Bernadette Connaughton

Companies

• Editas MedicineBoard member Oct 28, 2021 to now¹
• Halozyme TherapeuticsBoard member Sep 11, 2018 to now²
• Syneos Health, Inc.Board member Nov 14, 2019 to Sep 28, 2023³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• HTHalozyme Therapeutics HALO40,418 shares⁴$5.0M at $122.96Aug 10, 2026
• SHSyneos Health, Inc.0 shares⁵Sep 28, 2023
• Editas Medicine EDIT0 shares⁶Oct 28, 2021

As of each latest filing. The line shows shares held over time.

Recent filings

• Aug 10, 2026Sold 1,626 shares at $102.80 of Halozyme Therapeutics⁴
• Jul 1, 2026Sold 625 shares at $77.21 of Halozyme Therapeutics⁷
• Jul 1, 2026Sold 1,000 shares at $76.40 of Halozyme Therapeutics⁷
• Jun 1, 2026Sold 1,625 shares at $66.21 of Halozyme Therapeutics⁸
• May 5, 2026Granted 6,796 shares of Halozyme Therapeutics⁹
• May 1, 2026Sold 1,625 shares at $63.48 of Halozyme Therapeutics¹⁰
• Jan 5, 2026Sold 2,000 shares at $70.25 of Halozyme Therapeutics¹¹
• Dec 1, 2025Sold 829 shares at $71.60 of Halozyme Therapeutics¹²
• Nov 10, 2025Sold 2,000 shares at $68.48 of Halozyme Therapeutics¹³
• Oct 1, 2025Sold 500 shares at $75.70 of Halozyme Therapeutics¹⁴
• Oct 1, 2025Sold 1,500 shares at $75.09 of Halozyme Therapeutics¹⁴
• Sep 2, 2025Sold 923 shares at $74.11 of Halozyme Therapeutics¹⁵
• Sep 2, 2025Sold 2,977 shares at $73.62 of Halozyme Therapeutics¹⁵
• Sep 2, 2025Sold 100 shares at $71.71 of Halozyme Therapeutics¹⁵
• May 1, 2025Granted 4,165 shares of Halozyme Therapeutics¹⁶
• Apr 25, 2024Granted 6,501 shares of Halozyme Therapeutics¹⁷
• Sep 28, 2023Returned to company 4,863 shares of Syneos Health, Inc.⁵
• Sep 28, 2023Returned to company 9,915 shares at $43.00 of Syneos Health, Inc.⁵
• May 25, 2023Granted 4,863 shares of Syneos Health, Inc.¹⁸
• May 5, 2023Granted 8,065 shares of Halozyme Therapeutics¹⁹
• Nov 16, 2022Gift 5,998 shares of Halozyme Therapeutics²⁰
• May 25, 2022Granted 2,839 shares of Syneos Health, Inc.²¹
• May 5, 2022Granted 6,206 shares of Halozyme Therapeutics²²